Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

ANLABUS

Adlai Nortye Ltd.

ANL · $10.58

54Fair

Arbutus Biopharma Corp

ABUS · $4.20

78Strong

Area by area

Overall Quant Score

How does it look overall? (out of 100)

ANL

54/100

ABUS

78/100

Quality

Is it a profitable, well-run business?

ANL

2.0/10

ABUS

10.0/10

Growth

Is the company growing?

ANL

9.0/10

ABUS

8.0/10

Valuation

Is the price reasonable? (higher = cheaper)

ANL

0.0/10

ABUS

7.5/10

Risk

How risky are the shares? (higher = lower risk)

ANL

1.7/10

ABUS

7.3/10

Momentum

Is the share price trending up?

ANL

3.5/10

ABUS

5.5/10

Financial strength

Is the balance sheet healthy?

ANL

6.3/10

ABUS

9.0/10

The balanced view

Model-generated

Adlai Nortye Ltd.

This company has a mixed profile, with solid growth and supportive analyst views, although its current valuation deserves attention.

Leads on: growth

Best feature: solid growth (Forward revenue growth: 244.0%)

Watch out: valuation may be demanding (P/E (TTM): -5.4x)

Arbutus Biopharma Corp

This company scores well across most areas, with strong profitability and supportive analyst views.

Leads on: quality, valuation, risk, momentum, financial strength

Best feature: strong profitability (Return on equity (TTM): 91.0%)

Watch out: weakest area: price momentum (Signal consensus: Strong Sell)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.